3rd Annual

AML-ALL

Focus Meeting 2024

calendar icon

St. Ermin’s Hotel, London, UK

calendar icon

October 25 - 26, 2024

Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the AML-ALL Focus Meeting 2024, to be held at on October 25 - 26, 2024.

Centered around the theme “Updating Knowledge & Clinical Practice in 2024” this meeting provides pivotal collaboration aimed at advancing AML-ALL research and patient treatment.

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

Chairs of AML-ALL Focus Meeting 2024:

Headshot of Chair: Naval Daver, MD

Naval Daver, MD

MD Anderson Cancer Center, Houston, TX

Headshot of Chair: Elias Jabbour, MD

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX

Headshot of Chair: Cristina Papayannidis, MD

Cristina Papayannidis, MD

University of Bologna, Italy

Headshot of Chair: Charlie Craddock, MD

Charlie Craddock, MD

Queen Elizabeth Hospital, Birmingham, UK

Supporters to be announced...

Interested in supporting this meeting? Get in contact:

rebecca.hill@md-education.com

Agenda & Faculty

October 25, 2024 | Day 1

07:00 AM
Registration Opens
07:45 AM
Opening Remarks – Ryan Fitzpatrick, CEO, MD Education

Session I


Moderated by:

Headshot of Naval Daver, MD

Naval Daver, MD

MD Anderson Cancer Center, Houston, TX
08:00 AM
Research and Progress in AML
Headshot of Hagop Kantarjian, MD

Hagop Kantarjian, MD

MD Anderson Cancer Center, Houston, TX
08:20 AM
Practical Approach to Incorporating Genomics in Treatment Decision Making in Fit Adult AML
Headshot of Paresh Vyas, MD

Paresh Vyas, MD

University of Oxford, UK
08:40 AM
Incorporating MRD into Treatment Decision Making in Newly Diagnosed AML, Focus on NPM1 and FLT3 Mutated AML
Headshot of Christoph Röllig, MD

Christoph Röllig, MD

TU Dresden, Germany
09:00 AM
Current Status and Updates in the Diagnosis, Prognosis and Management of Secondary and Therapy Related AML
Headshot of Priyanka Mehta, MD

Priyanka Mehta, MD

University Hospitals Bristol NHS Foundation Trust, UK
09:20 AM
Optimising Transplant Outcomes in High-risk AML?
Headshot of Charlie Craddock, MD

Charlie Craddock, MD

Queen Elizabeth Hospital, Birmingham, UK
09:40 AM
Panel Discussion
10:00 AM
Coffee Break

Session II


Moderated by:

Headshot of Cristina Papayannidis, MD

Cristina Papayannidis, MD

University of Bologna, Italy
10:20 AM
Biology of Ph Pos ALL: New Insights for a Risk Stratification?
Headshot of Ilaria Iacobucci, MD

Ilaria Iacobucci, MD

St. Jude Children’s Research Hospital, Memphis, TN
10:40 AM
How I Treat Ph Positive ALL in 2024: US
Headshot of Elias Jabbour, MD

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX
11:00 AM
How I Treat Ph Positive ALL in 2024: Europe
Headshot of Robin Foà, MD

Robin Foà, MD

University of Rome, Italy
11:20 AM
SCT in Ph+ ALL: is it Still Necessary?
Headshot of Emmanuelle Clappier, MD

Emmanuelle Clappier, MD

Hôpital Saint-Louis, France
11:40 AM
Open Issues in Pediatric ALL
Headshot of Rob Pieters, MD

Rob Pieters, MD

The Princess Máxima Center, Utrecht, Netherlands
12:00 PM
Panel Discussion
12:20 PM
Lunch Break, Networking, and Faculty & Fellow Photo

Session III


Moderated by:

Headshot of Charlie Craddock, MD

Charlie Craddock, MD

Queen Elizabeth Hospital, Birmingham, UK
01:10 PM
Which Patients with Newly Diagnosed AML Should Receive a Venetoclax Based Regimen in 2024
Headshot of Naval Daver, MD

Naval Daver, MD

MD Anderson Cancer Center, Houston, TX
01:30 PM
Menin Inhibitors in the Management of AML
Headshot of Emma Searle, MD

Emma Searle, MD

The Christie NHS Foundation Trust, Manchester, UK
01:50 PM
Immunotherapeutic Strategies in AML
Headshot of Marion Subklewe, MD

Marion Subklewe, MD

University Hospital of Munich, Germany
02:10 PM
Management of Disease Relapse in Fit and Unfit AML Patients
Headshot of Alessandro Isidori, MD

Alessandro Isidori, MD

Marche Nord Hospital, Italy
02:30 PM
Panel Discussion
02:50 PM
Coffee Break & Networking

Session IV


Moderated by:

Headshot of Elias Jabbour, MD

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX
03:10 PM
SCT in Adult Ph Neg ALL: How, When and for Which Patients?
Headshot of Anna Castleton, MD

Anna Castleton, MD

The Christie NHS Foundation Trust, Manchester, UK
03:30 PM
CAR-T Cells in ALL: Progress and Pitfalls
Headshot of Marion Subklewe, MD

Marion Subklewe, MD

University Hospital of Munich, Germany

Debate: R/R Ph Neg ALL: CAR-T Cells or Antibodies?

03:50 PM
CAR-T Cells
Headshot of Claire Roddie, MD

Claire Roddie, MD

University of London, UK
04:00 PM
Antibodies
Headshot of Nicolas Boissel, MD

Nicolas Boissel, MD

Assistance Publique – Hôpitaux de Paris, France
04:10 PM
Panel & Debate Discussion
04:30 PM
Adjourn

October 26, 2024 | Day 2

08:00 AM
Registration Opens

Session V


Moderated by:

Headshot of Alessandro Rambaldi, MD

Alessandro Rambaldi, MD

Università degli Studi di Milano, Italy
08:40 AM
Evolving Front-line Treatment Options and Treatment Journey in FLT3 Mutated AML Patients Eligible for Intensive Chemotherapy
Headshot of Stéphane de Botton, MD

Stéphane de Botton, MD

Institut Gustave Roussy, Villejuif, France
09:00 AM
Treatment of APML in 2024
Headshot of Maria Teresa Voso, MD

Maria Teresa Voso, MD

Rome Tor Vergata University, Italy
09:20 AM
Addressing Inequity of Outcomes and Accessing Patients with AML
Headshot of Pramila Krishnamurthy, MD

Pramila Krishnamurthy, MD

King’s College Hospital NHS Foundation Trust, London, UK
09:40 AM
Optimising Outcomes and Practical Pointers in Patients Treated with HMA+venetoclax Based Regimen
Headshot of Michael Dennis, MD

Michael Dennis, MD

The Christie NHS Foundation Trust, Manchester, UK
10:00 AM
Panel Discussion
10:20 AM
Coffee Break

Session VI


Moderated by:

Headshot of Emmanuelle Clappier, MD

Emmanuelle Clappier, MD

Hôpital Saint-Louis, France
10:40 AM
MRD in ALL: How can we Measure it?
Headshot of Monika Brüggemann, MD

Monika Brüggemann, MD

Universitätsklinikum Schleswig - Holstein, Kiel, Germany
11:00 AM
Treatment Strategies to Eradicate MRD
Headshot of Cristina Papayannidis, MD

Cristina Papayannidis, MD

University of Bologna, Italy
11:20 AM
Treatment Strategies in Ph Like ALL
Headshot of Giovanni Martinelli, MD

Giovanni Martinelli, MD

MD Anderson Cancer Center, Houston, TX
11:40 AM
Panel Discussion

Debate: First Line Approaches in Ph Neg ALL in 2024

12:00 PM
AYA
Headshot of Anna Castleton, MD

Anna Castleton, MD

The Christie NHS Foundation Trust, Manchester, UK
12:20 PM
Adult
Headshot of Sabina Chiaretti, MD

Sabina Chiaretti, MD

Sapienza Università di Roma, Italy
12:40 PM
Elderly
Headshot of Elias Jabbour, MD

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX
01:00 PM
Panel Discussion
01:20 PM
Lunch Break, Networking, and Faculty & Fellow Photo

Session VII


Moderated by:

Headshot of Hagop Kantarjian, MD

Hagop Kantarjian, MD

MD Anderson Cancer Center, Houston, TX

Debate: MRD Technology is an Expensive Luxury in the Management of the Majority of Fit Adults with Newly Diagnosed AML

02:10 PM
YES to MRD is a Luxury and Not Applicable/valuable for Majority of AML
Headshot of Victoria Potter, MD

Victoria Potter, MD

King’s College Hospital NHS Foundation Trust, London, UK
Headshot of Jurjen Versluis, MD

Jurjen Versluis, MD

Erasmus University, Rotterdam, Netherlands
02:30 PM
NO to MRD is a Luxury: MRD is Valuable in Treatment Decision Making and Should be Included in all Newly Diagnosed AML FOR PRO MRD use
Headshot of Felicitas Thol, MD

Felicitas Thol, MD

Hannover Medical School, Germany
Headshot of Alessandro Rambaldi, MD

Alessandro Rambaldi, MD

Università degli Studi di Milano, Italy
02:50 PM
Updates in AML Classification Systems and Incorporating Molecular Information into Optimizing Future Classification Systems to Help Optimally Guide Treatment Decision Making
Headshot of Sanam Loghavi, MD

Sanam Loghavi, MD

MD Anderson Cancer Center, Houston, TX
03:10 PM
Myelodysplastic Syndromes in 2024
Headshot of Rami Komrokji, MD

Rami Komrokji, MD

Moffitt Cancer Center, Tampa, FL
03:30 PM
Panel & Debate Discussion
03:50 PM
Coffee Break & Networking

Session VIII


Moderated by:

Headshot of Anna Castleton, MD

Anna Castleton, MD

The Christie NHS Foundation Trust, Manchester, UK
04:10 PM
CNS Prophylaxis in ALL
Headshot of Sebastian Giebel, MD

Sebastian Giebel, MD

Maria Sklodowska-Curie Cancer Center, Poland
04:30 PM
Universita di Bologna, Italy New Targets in ALL
Headshot of Cristina Papayannidis, MD

Cristina Papayannidis, MD

University of Bologna, Italy
04:50 PM
Advances in T-ALL: from Chemotherapy to CAR-T cells
Headshot of Jan Cools, MD

Jan Cools, MD

KU Leuven, Belgium
05:10 PM
Panel Discussion
05:30 PM
Take-home Points & Adjourn

Rebecca Hill

Project Manager

How long has Rebecca Hill been in the business?

Rebecca Hill has been with MD Education since 2022

About Rebecca Hill

I am a dedicated Senior Project Manager at MD Education, specialising in coordinating global medical conferences. I have a passion for organisation and detail, and I pride myself on ensuring seamless execution of educational events. My expertise lies in orchestrating logistics and fostering collaboration among diverse teams.